JP2018507169A - 担体分子組成物および関連方法 - Google Patents
担体分子組成物および関連方法 Download PDFInfo
- Publication number
- JP2018507169A JP2018507169A JP2017531629A JP2017531629A JP2018507169A JP 2018507169 A JP2018507169 A JP 2018507169A JP 2017531629 A JP2017531629 A JP 2017531629A JP 2017531629 A JP2017531629 A JP 2017531629A JP 2018507169 A JP2018507169 A JP 2018507169A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- gly
- composition
- carrier molecule
- botulinum toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title description 28
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims abstract description 36
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims abstract description 36
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 22
- 239000002502 liposome Substances 0.000 claims abstract description 10
- 239000000693 micelle Substances 0.000 claims abstract description 8
- 108030001720 Bontoxilysin Proteins 0.000 claims description 66
- 229940053031 botulinum toxin Drugs 0.000 claims description 62
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 13
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 12
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 12
- 229930002330 retinoic acid Natural products 0.000 claims description 11
- 229960001727 tretinoin Drugs 0.000 claims description 11
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 239000006174 pH buffer Substances 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 6
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 6
- 229960004373 acetylcholine Drugs 0.000 claims description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- 229960001680 ibuprofen Drugs 0.000 claims description 6
- 229960002009 naproxen Drugs 0.000 claims description 6
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 6
- 229960005489 paracetamol Drugs 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- RLCSROTYKMPBDL-USJZOSNVSA-N 2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-methylbutanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical group CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RLCSROTYKMPBDL-USJZOSNVSA-N 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 239000002858 neurotransmitter agent Substances 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108010011876 valyl-glycyl-valyl-alanyl-prolyl-glycine Proteins 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- 239000007933 dermal patch Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 230000037317 transdermal delivery Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 37
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 238000009472 formulation Methods 0.000 description 8
- 230000032258 transport Effects 0.000 description 7
- 206010033799 Paralysis Diseases 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 150000001720 carbohydrates Chemical group 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000002581 neurotoxin Substances 0.000 description 4
- 231100000618 neurotoxin Toxicity 0.000 description 4
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000001151 peptidyl group Chemical group 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- -1 steroid compounds Chemical class 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010054404 Adenylyl-sulfate kinase Proteins 0.000 description 3
- 101710138657 Neurotoxin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100039024 Sphingosine kinase 1 Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000001097 facial muscle Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KANINNSSRWMGIP-UHFFFAOYSA-M sodium;butyl 4-hydroxybenzoate;dodecyl sulfate;hexadecan-1-ol;methyl 4-hydroxybenzoate;octadecan-1-ol;propane-1,2-diol;propyl 4-hydroxybenzoate Chemical compound [Na+].CC(O)CO.COC(=O)C1=CC=C(O)C=C1.CCCOC(=O)C1=CC=C(O)C=C1.CCCCOC(=O)C1=CC=C(O)C=C1.CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCO KANINNSSRWMGIP-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XUNKPNYCNUKOAU-VXJRNSOOSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUNKPNYCNUKOAU-VXJRNSOOSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OWPUOLBODXJOKH-UHFFFAOYSA-N 2,3-dihydroxypropyl prop-2-enoate Chemical compound OCC(O)COC(=O)C=C OWPUOLBODXJOKH-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000017011 Mandorlo dulce Nutrition 0.000 description 1
- 244000076313 Mandorlo dulce Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
Abstract
Description
本願は、Tanらの「Carrier Molecule Compositions and Related Methods」と題する、2014年12月8日に出願のされた米国仮特許出願第62/088,813号(’813仮出願)の出願日の利益を主張し、その開示内容の全ては、参照することにより本明細書に組み込まれる。
ASCIIテキスト形式で2015年12月8日に提出されたSequenceListing003_ST25.txt(2015年12月8日作成。サイズ11,515バイト)の配列表は参照することにより、その全ては本明細書に組み込まれる。
バックグラウンド
本明細書の態様は概して、生物学的に活性な分子を送達するために使用される組成物および方法に関する。より具体的な実施形態として、生物学的に活性な分子を経皮的に送達することができる組成物が含まれる。
生物学的に活性な分子は、ヒトまたは動物の体内で様々な生化学的変化を遂行、関与、または開始することができる。例えば、ボツリヌス毒素は、筋肉の麻痺を引き起こし、皮膚のしわを治療するために使用される神経毒として作用する生物学的に活性な分子である。ボツリヌス毒素は、通常、注射によって皮膚に投与される。皮膚の構造、皮膚のしわ、しわの治療方法、およびボツリヌス毒素に関する更なる背景情報は以下の参考文献に見出すことができ、これらの各々の開示は参照によりその全ては本明細書に組み込まれる:Inlander, Skin, New York, N.Y.: People’s Medical Society, p. 1-7 (1998); Benedetto, International Journal of Dermatology, V. 38, p. 641-655 (1999); Stegman et al., “The Skin of the Aging Face,” Cosmetic Dermatological Surgery, 2nd ed., St. Louis, Mo.: Mosby Year Book: p. 5-15 (1990); Lamanna, Science, V. 130, p. 763-772 (1959); Baron et al., Bailey & Scotts Diagnostic Microbiology, St. Louis, Mo.: Mosby Year Book, p. 504-523 (1994); Carruthers and Carruthers, Adv. Dermatol., V. 12, p. 325-348 (1997); Markowitz, Hunters Tropical Medicine, 7th Ed., Philadelphia: W. B. Saunders, p. 441-444 (1991); Schantz and Scott, Biomedical Aspects of Botulinum, New York: Academic Press, p. 143-150 (1981); and Scott, Ophthalmol, V. 87, p. 1044-1049 (1980)。
組成物の実施形態は、少なくとも1つの細胞浸透性ペプチド(CPP)を含む担体分子を含み、当該担体分子は少なくとも1つの疎水性ドメインを含み得、当該担体はミセルおよびリポソームの1つにおいて生物学的に活性な分子と非共有的に結合している。
この開示、その態様および実施形態は、本明細書に開示される特定の構成要素、アセンブリ手順または方法要素に限定されない。本開示から、特定の実施形態と共に使用される、意図された担体分子組成物、キット、および関連する方法の実施形態と一致する、当技術分野で公知の多くの追加的な構成要素、アセンブリ手順および/または方法要素は、明らかになるであろう。したがって、例えば、特定の実施形態が開示されているが、そのような実施形態および実施構成要素は、意図された操作および方法と一致する、当該担体分子組成物、キット、および関連する方法、ならびに構成要素および方法の実施の技術分野において公知である任意の形状、サイズ、スタイル、タイプ、モデル、バージョン、測定、濃度、材料、量、方法要素、ステップなどを含みうる。
の特定の実施形態について言及するとき、その精神から逸脱することなく様々な改変はなされうること、およびこれらの実施形態、実施形態のコンポーネント、サブコンポーネント、方法およびサブ方法は、他の担体分子組成物、キット、および関連する方法の実施形態に適用されうるは容易に明らかである。
Claims (20)
- 少なくとも1つの細胞透過性ペプチド(CPP)を含む担体分子(当該担体分子は少なくとも1つの疎水性ドメインを含む)を含む組成物であって、該担体は、ミセルおよびリポソームの1つ中で生物学的に活性な分子と非共有的に結合することを特徴とする、組成物。
- 該担体分子が両親媒性である、請求項1に記載の組成物。
- 該担体分子が少なくとも1つの炭水化物部分を含む、請求項1に記載の組成物。
- 該担体分子が少なくとも1つのアルキル鎖を含む、請求項1に記載の組成物。
- 該担体分子が少なくとも3つの疎水性アミノ酸を含む、請求項1に記載の組成物。
- 該担体分子が少なくとも1つのフェニルアラニンを含む、請求項1に記載の組成物。
- 該担体分子がパルミトイル−glyp−KKRPKPG(配列番号5)、オクタノイル−glyp−KKRPKPG(配列番号6)、オレイル−glyp−KKRPKPG(配列番号7)、およびそれらの任意の組み合わせ(pは0〜20の整数である)の1つを含む、請求項1に記載の組成物。
- 該担体分子がFFFILVF−glyp−KKRPKPG(配列番号1)、FLVFFF−glyp−KKRPKPG(配列番号2)、KKRPKPG−glyp−FLVFFF(配列番号3)、およびそれらの任意の組み合わせ(pは0〜10の整数である)からなる群から選択される、請求項1に記載の組成物。
- 該少なくとも1つのCPPが、式(gly)p−RGRDDRRQRRR−(gly)q(配列番号8)を有するフラグメント、式(gly)p−YGRKKRRQRRR−(gly)q(配列番号9)を有するフラグメント、式(gly)p−RKKRRQRRR−(gly)q(配列番号10)を有するフラグメント(下付き文字pおよびqは各々独立して0〜20の整数である)からなる群から選択されるHIV−TATフラグメント;KKRPKPG(配列番号17);AAVLLPVLLAAP(配列番号15)、およびそれらの任意の組み合わせからなる群から選択される、請求項1に記載の組成物。
- 該生物学的に活性な分子が、VGVAPG(配列番号26);パルミトイル−TTS;レチノイン酸レチニル;レチノイン酸;ステロイドおよびステロイド化合物;ヒドロキノン;ヒアルロン酸;非ステロイド性抗炎症薬(NSAID)、例えばナプロキセン、イブプロフェン、およびアセトアミノフェン;皮膚引き締めペプチド;光活性化可能な部分および化合物;紫外線(UV)光を吸収、ブロック、または反射する化合物;ビタミン;コレステロール;神経伝達物質(アセチルコリンなど)の機能を遮断、影響、または妨害する薬物;およびそれらの任意の組み合わせからなる群から選択される、請求項1に記載の組成物。
- 該生物学的に活性な分子が:A、B、C、D、E、F、およびGからなる群から選択されるボツリヌス毒素血清型;組換えボツリヌス毒素;修飾ボツリヌス毒素;ボツリヌス毒素のフラグメント;およびそれらの任意の組み合わせ;からなる群から選択される、請求項1に記載の組成物。
- 生物学的に活性な分子、および
少なくとも1つの親油性ドメインおよび少なくとも1つの細胞透過性ペプチド(CPP)を含む担体分子
を含む組成物であって;
該担体分子はさらに、
少なくとも1つの炭水化物部分、
少なくとも1つのアルキル鎖、
少なくとも三つの疎水性アミノ酸、および
これらの任意の組み合わせ
の1つを含み;
該担体分子と該生物学的に活性な分子は非共有的に結合する、組成物。 - 該担体分子が、パルミトイル−glyp−KKRPKPG(配列番号5)、オクタノイル−glyp−KKRPKPG(配列番号6)、オレイル−glyp−KKRPKPG(配列番号7)、およびそれらの任意の組み合わせ(pは0〜20の整数である)の1つを含む、請求項12に記載の組成物。
- 該担体分子がFFFILVF−glyp−KKRPKPG(配列番号1)、FLVFFF−glyp−KKRPKPG(配列番号2)、KKRPKPG−glyp−FLVFFF(配列番号3)、およびそれらの任意の組み合わせ(pは0〜10の整数である)からなる群から選択される、請求項12に記載の組成物。
- 該少なくとも1つのCPPが式(gly)p−RGRDDRRQRRR−(gly)q(配列番号8)を有するフラグメント、式(gly)p−YGRKKRRQRRR−(gly)q(配列番号9)を有するフラグメント、式(gly)p−RKKRRQRRR−(gly)q(配列番号10)を有するフラグメント(下付き文字pおよびqは各々独立して0〜20の整数である)からなる群から選択されるHIV−TATフラグメント;KKRPKPG(配列番号17);AAVLLPVLLAAP(配列番号15)、およびそれらの任意の組み合わせからなる群から選択される、請求項12に記載の組成物。
- 該生物学的に活性な分子が、VGVAPG(配列番号26);パルミトイル−TTS;レチノイン酸レチニル;レチノイン酸;ステロイドおよびステロイド化合物;ヒドロキノン;ヒアルロン酸;非ステロイド性抗炎症薬(NSAID)、例えばナプロキセン、イブプロフェン、およびアセトアミノフェン;皮膚引き締めペプチド;光活性化可能な部分および化合物;紫外線(UV)光を吸収、ブロック、または反射する化合物;ビタミン;コレステロール;神経伝達物質(アセチルコリンなど)の機能を遮断、影響、または妨害する薬物;およびそれらの任意の組み合わせからなる群から選択される、請求項12に記載の組成物。
- 該生物学的に活性な分子が:A、B、C、D、E、F、およびGからなる群から選択されるボツリヌス毒素血清型;組換えボツリヌス毒素;修飾ボツリヌス毒素;ボツリヌス毒素のフラグメント;およびそれらの任意の組み合わせ;からなる群から選択される、請求項12に記載の組成物。
- 患者にボツリヌス毒素を投与するためのキットであって;
該キットは、
ボツリヌス毒素、
その経皮送達のための有効量の担体分子(該担体分子は少なくとも1つの細胞透過性ペプチド(CPP)を含み、かつ、少なくとも1つの疎水性ドメインを含む)、
4.0〜8.3のpHを維持するように調整されたpH緩衝系、および
該ボツリヌス毒素、該担体分子、および該pH緩衝系を含むデバイス(該デバイスは患者の皮膚を介して患者にボツリヌス毒素を投与するのに適合されている)
を含み;
該担体分子は、ミセルおよびリポソームの1つ中で、ボツリヌス毒素と非共有的に結合し;および
該デバイス、該担体分子、該pH緩衝系、およびその任意の組み合わせの1つは、該ボツリヌス毒素の制御放出を提供するように適合されている、キット。 - 該デバイスが、皮膚パッチである、請求項18に記載のキット。
- 該ボツリヌス毒素、該担体分子、および該pH緩衝系が、該デバイスに結合された液体、ゲル、クリーム、ローション、および軟膏中に含まれる、請求項18に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462088813P | 2014-12-08 | 2014-12-08 | |
US62/088,813 | 2014-12-08 | ||
PCT/IB2015/002430 WO2016092365A1 (en) | 2014-12-08 | 2015-12-08 | Carrier molecule compositions and related methods |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018507169A true JP2018507169A (ja) | 2018-03-15 |
JP6821866B2 JP6821866B2 (ja) | 2021-01-27 |
Family
ID=56106788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017531629A Active JP6821866B2 (ja) | 2014-12-08 | 2015-12-08 | 担体分子組成物および関連方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20160166703A1 (ja) |
EP (1) | EP3230302A4 (ja) |
JP (1) | JP6821866B2 (ja) |
KR (1) | KR102497642B1 (ja) |
CN (1) | CN107427548A (ja) |
AU (1) | AU2015359030B2 (ja) |
CA (1) | CA2970136C (ja) |
HK (1) | HK1245302A1 (ja) |
IL (1) | IL252738B (ja) |
SG (1) | SG11201704699YA (ja) |
WO (1) | WO2016092365A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201704699YA (en) | 2014-12-08 | 2017-07-28 | JJSK R&D Pte Ltd | Carrier molecule compositions and related methods |
CN109803673A (zh) | 2016-09-13 | 2019-05-24 | 阿勒根公司 | 非蛋白质梭菌毒素组合物 |
WO2018148338A1 (en) * | 2017-02-07 | 2018-08-16 | Lars Erik Peters | Topical formulations and methods |
US20210162026A1 (en) | 2017-08-28 | 2021-06-03 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
KR102293250B1 (ko) * | 2017-09-18 | 2021-08-26 | 애니젠 주식회사 | 활성물질-헥사펩타이드 복합체 및 이를 포함하는 화장료 조성물 |
US20200390871A1 (en) * | 2017-11-03 | 2020-12-17 | Revance Therapeutics, Inc. | Botulinum toxin formulations and methods of use thereof in plantar fascitis with extended duration of effect |
BR112020011098A2 (pt) * | 2017-12-04 | 2020-11-17 | Revance Therapeutics, Inc. | formulações injetáveis de toxina botulínica e métodos de uso das mesmas que têm alta taxa de resposta e longa duração de efeito |
CN109091413A (zh) * | 2018-10-31 | 2018-12-28 | 成都元素平衡生物科技有限公司 | 一种透皮性a型肉毒毒素、其制备方法及应用 |
KR20200080179A (ko) * | 2018-12-26 | 2020-07-06 | 아미코젠주식회사 | 아세틸콜린 수용체 저해 펩타이드 및 이의 용도 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531732A (ja) * | 2005-03-03 | 2008-08-14 | ルバンス セラピュティックス インク. | ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法 |
JP2009532017A (ja) * | 2006-02-10 | 2009-09-10 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | PTD/CPPSへのdsRNA結合ドメイン融合体によるsiRNAの導入可能な送達 |
US20120195957A1 (en) * | 2009-04-30 | 2012-08-02 | Mandip Singh Sachdeva | Novel nanoparticle formulations for skin delivery |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6780846B1 (en) * | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
CA2445947A1 (en) * | 2001-04-30 | 2002-11-07 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
PT1729821E (pt) | 2004-03-03 | 2013-10-23 | Revance Therapeutics Inc | Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas |
WO2005117928A1 (en) * | 2004-05-30 | 2005-12-15 | Cemines, Inc. | Compositions and methods for the treatment of skin cancer |
CN101616682A (zh) * | 2006-12-29 | 2009-12-30 | 雷文斯治疗公司 | 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法 |
CN102811744A (zh) * | 2008-09-16 | 2012-12-05 | 卡里姆·阿梅德 | 用于改善基因调节化合物的递送的化学修饰的细胞渗透性肽 |
DK2413947T3 (da) * | 2009-04-01 | 2020-06-02 | Revance Therapeutics Inc | Fremgangsmåder og sammensætninger til behandling af hudtilstande forbundet med vaskulær hyperreaktivitet |
WO2012090150A2 (en) * | 2010-12-27 | 2012-07-05 | Compugen Ltd | New cell-penetrating peptides and uses thereof |
WO2014183017A1 (en) * | 2013-05-09 | 2014-11-13 | KIPPERMAN, Richard, M. as Chapter 7 Bankruptcy Trustee for TRAVERSA THERAPEUTICS, INC. | Improved delivery of rna interfering agents |
SG11201704699YA (en) | 2014-12-08 | 2017-07-28 | JJSK R&D Pte Ltd | Carrier molecule compositions and related methods |
-
2015
- 2015-12-08 SG SG11201704699YA patent/SG11201704699YA/en unknown
- 2015-12-08 US US14/963,155 patent/US20160166703A1/en not_active Abandoned
- 2015-12-08 JP JP2017531629A patent/JP6821866B2/ja active Active
- 2015-12-08 EP EP15868632.9A patent/EP3230302A4/en active Pending
- 2015-12-08 KR KR1020177018816A patent/KR102497642B1/ko active IP Right Grant
- 2015-12-08 AU AU2015359030A patent/AU2015359030B2/en active Active
- 2015-12-08 CA CA2970136A patent/CA2970136C/en active Active
- 2015-12-08 CN CN201580076045.XA patent/CN107427548A/zh active Pending
- 2015-12-08 WO PCT/IB2015/002430 patent/WO2016092365A1/en active Application Filing
-
2017
- 2017-06-07 IL IL252738A patent/IL252738B/en unknown
- 2017-12-13 US US15/841,059 patent/US11484595B2/en active Active
-
2018
- 2018-04-17 HK HK18104955.5A patent/HK1245302A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531732A (ja) * | 2005-03-03 | 2008-08-14 | ルバンス セラピュティックス インク. | ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法 |
JP2009532017A (ja) * | 2006-02-10 | 2009-09-10 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | PTD/CPPSへのdsRNA結合ドメイン融合体によるsiRNAの導入可能な送達 |
US20120195957A1 (en) * | 2009-04-30 | 2012-08-02 | Mandip Singh Sachdeva | Novel nanoparticle formulations for skin delivery |
Non-Patent Citations (4)
Title |
---|
EUR J PHARM BIOPHARM, vol. 86, no. 2, JPN6019048881, 2014, pages 190 - 199, ISSN: 0004173367 * |
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 441, JPN6019048882, 2013, pages 748 - 756, ISSN: 0004173368 * |
JOURNAL OF MATERIALS CHEMISTRY B, vol. 2, JPN6019048884, 2014, pages 877 - 884, ISSN: 0004173369 * |
PNAS, vol. 99, no. 7, JPN6019048885, 2002, pages 4489 - 4494, ISSN: 0004173370 * |
Also Published As
Publication number | Publication date |
---|---|
CA2970136A1 (en) | 2016-06-16 |
US11484595B2 (en) | 2022-11-01 |
SG11201704699YA (en) | 2017-07-28 |
KR102497642B1 (ko) | 2023-02-09 |
AU2015359030A1 (en) | 2017-07-13 |
CA2970136C (en) | 2023-07-04 |
EP3230302A4 (en) | 2018-10-10 |
IL252738A0 (en) | 2017-08-31 |
EP3230302A1 (en) | 2017-10-18 |
WO2016092365A1 (en) | 2016-06-16 |
CN107427548A (zh) | 2017-12-01 |
KR20170093925A (ko) | 2017-08-16 |
US20160166703A1 (en) | 2016-06-16 |
JP6821866B2 (ja) | 2021-01-27 |
HK1245302A1 (zh) | 2018-08-24 |
IL252738B (en) | 2021-10-31 |
US20180214557A1 (en) | 2018-08-02 |
AU2015359030B2 (en) | 2020-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6821866B2 (ja) | 担体分子組成物および関連方法 | |
US10286030B2 (en) | Compositions and methods for invasive and non-invasive procedural skincare | |
JP5095388B2 (ja) | ボツリヌストキシンの局所適用及び経皮送達のための組成物及び方法 | |
JP2023179467A (ja) | 投与および処置の方法 | |
KR20070110402A (ko) | 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법 | |
US20210346458A1 (en) | Compositions and methods for improving bruising and rejuvenating skin | |
MX2010013562A (es) | Aplicacion dermica. | |
JP2009516700A (ja) | 低減された非毒素タンパク質を含むボツリヌス毒素の局所適用及び経皮送達のための組成物及び方法 | |
JP7110405B2 (ja) | 筋肉弛緩用組成物 | |
JP2006528645A (ja) | ざ瘡の処置のための、xmp−629の使用 | |
EA038613B1 (ru) | Смешанные составы | |
ITMI20111806A1 (it) | Composizione per il trattamento delle lesioni cutanee | |
US20080200400A1 (en) | Dermatological compositions including oligopeptides for increasing skin sensitivity and neuronal perception | |
US20100261658A1 (en) | Peptide for activating aquaporin synthesis | |
JP2024511804A (ja) | 化粧剤の送達のためのマルチソーム脂質小胞 | |
KR102267190B1 (ko) | 나노 리포좀 처리 공법에 의해 우수한 보습력 및 피부 침투 효과를 갖는 인공크림막 조성물 | |
US20230355493A1 (en) | Topical composition | |
CN113453675A (zh) | 辛酸和癸酸甘油三酯用于治疗由丝聚蛋白或胶原蛋白缺乏介导的疾病或病症的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191217 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200316 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200616 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200901 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200930 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201030 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20201201 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6821866 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |